Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Miller who wrote (3164)	6/2/1999 4:41:00 PM
From: Bob Swift	Read Replies (1) of 10280

Even though Xopenex is better and the data support the hypothesis that the S isomer has problem, it is nonetheless a hypothesis which needs to be proved conclusively by further experiments (e.g. feed people with S isomer and watch them get sick or collect statistical data over long period of time to show how bad albuterol is compare to Xopenex). Of all people, the CEO (as a scientist) knows that but SEPR is still not skillful in writing around the concerns of the FDA which goes by the book. One way to do this is to write the promotional material twice. First write it as the scientific data allow (limit) and then rewrite it to bring out the hypothesis. It really is not that difficult to write in such a way so both SEPR and the FDA win. SEPR management needs to wake up and hire someone to do the careful writing of promotional material. There will be ICE that are black and white and there will be gray ones and this problem will not go away. Let the writing be conservative but leave room in writing for the sales to expand on orally. The market is fighting the FED today, I don't like that.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next